Sphera Funds Management’s Teva Pharmaceuticals TEVA Stock Holding History

Sphera Funds Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-210,000	Closed	-$1.97M	–	81
2022 Q1	$1.97M	Buy	+210,000	New	+$1.75M	0.28%	55
2017 Q4	–	Sell	-72,000	Closed	-$1.27M	–	150
2017 Q3	$1.27M	Buy	72,000 +70,880	+6,329%	+$1.59M	0.18%	98
2017 Q2	$3.6M	Buy	+1,120	New	+$34.7K	0.61%	50
2014 Q3	–	Sell	-1,000	Closed	-$80K	–	143
2014 Q2	$80K	Buy	+1,000	New	+$51.1K	0.02%	94

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sphera Funds Management's TEVA Position: Q1 2026 in Review

Sphera Funds Management increased its Teva Pharmaceuticals (TEVA) stake by 1.2% in Q1 2026, buying an estimated $433K and bringing the position to 1,136,975 shares worth $34.2M. The position accounts for 5.44% of the portfolio, ranked #2.

Sphera Funds Management first reported a position in TEVA in Q4 2013 and has held it in 45 quarters since. The position peaked at $51.5M in Q4 2015. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

Sphera Funds Management held 1,136,975 shares of Teva Pharmaceuticals worth $34.2M as of Q1 2026.
Sphera Funds Management bought 13,450 Teva Pharmaceuticals shares in Q1 2026, an estimated $433K.
Teva Pharmaceuticals made up 5.44% of Sphera Funds Management's portfolio in Q1 2026, its #2 holding.
Sphera Funds Management first reported a position in Teva Pharmaceuticals in Q4 2013 and has held it in 45 quarters since.
Sphera Funds Management's Teva Pharmaceuticals position peaked at $51.5M in Q4 2015.
650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Sphera Funds Management's 13F filing for Q1 2026, filed 15 May 2026.